Literature DB >> 30740441

Immunotherapy in first line for extensive-stage small-cell lung cancer: another piece is going to fill the puzzle?

Francesco Passiglia1, Silvia Novello1.   

Abstract

Entities:  

Year:  2018        PMID: 30740441      PMCID: PMC6330599          DOI: 10.21037/atm.2018.12.25

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN: 2305-5839


× No keyword cloud information.
  17 in total

Review 1.  Small Cell Lung Cancer: Can Recent Advances in Biology and Molecular Biology Be Translated into Improved Outcomes?

Authors:  Paul A Bunn; John D Minna; Alexander Augustyn; Adi F Gazdar; Youcef Ouadah; Mark A Krasnow; Anton Berns; Elisabeth Brambilla; Natasha Rekhtman; Pierre P Massion; Matthew Niederst; Martin Peifer; Jun Yokota; Ramaswamy Govindan; John T Poirier; Lauren A Byers; Murry W Wynes; David G McFadden; David MacPherson; Christine L Hann; Anna F Farago; Caroline Dive; Beverly A Teicher; Craig D Peacock; Jane E Johnson; Melanie H Cobb; Hans-Guido Wendel; David Spigel; Julien Sage; Ping Yang; M Catherine Pietanza; Lee M Krug; John Heymach; Peter Ujhazy; Caicun Zhou; Koichi Goto; Afshin Dowlati; Camilla Laulund Christensen; Keunchil Park; Lawrence H Einhorn; Martin J Edelman; Giuseppe Giaccone; David E Gerber; Ravi Salgia; Taofeek Owonikoko; Shakun Malik; Niki Karachaliou; David R Gandara; Ben J Slotman; Fiona Blackhall; Glenwood Goss; Roman Thomas; Charles M Rudin; Fred R Hirsch
Journal:  J Thorac Oncol       Date:  2016-01-30       Impact factor: 15.609

2.  Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer.

Authors:  Leena Gandhi; Delvys Rodríguez-Abreu; Shirish Gadgeel; Emilio Esteban; Enriqueta Felip; Flávia De Angelis; Manuel Domine; Philip Clingan; Maximilian J Hochmair; Steven F Powell; Susanna Y-S Cheng; Helge G Bischoff; Nir Peled; Francesco Grossi; Ross R Jennens; Martin Reck; Rina Hui; Edward B Garon; Michael Boyer; Belén Rubio-Viqueira; Silvia Novello; Takayasu Kurata; Jhanelle E Gray; John Vida; Ziwen Wei; Jing Yang; Harry Raftopoulos; M Catherine Pietanza; Marina C Garassino
Journal:  N Engl J Med       Date:  2018-04-16       Impact factor: 91.245

Review 3.  The blockade of immune checkpoints in cancer immunotherapy.

Authors:  Drew M Pardoll
Journal:  Nat Rev Cancer       Date:  2012-03-22       Impact factor: 60.716

4.  Pembrolizumab in Patients With Extensive-Stage Small-Cell Lung Cancer: Results From the Phase Ib KEYNOTE-028 Study.

Authors:  Patrick A Ott; Elena Elez; Sandrine Hiret; Dong-Wan Kim; Anne Morosky; Sanatan Saraf; Bilal Piperdi; Janice M Mehnert
Journal:  J Clin Oncol       Date:  2017-08-16       Impact factor: 44.544

Review 5.  Molecular and cellular insights into T cell exhaustion.

Authors:  E John Wherry; Makoto Kurachi
Journal:  Nat Rev Immunol       Date:  2015-08       Impact factor: 53.106

6.  Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial.

Authors:  Scott J Antonia; José A López-Martin; Johanna Bendell; Patrick A Ott; Matthew Taylor; Joseph Paul Eder; Dirk Jäger; M Catherine Pietanza; Dung T Le; Filippo de Braud; Michael A Morse; Paolo A Ascierto; Leora Horn; Asim Amin; Rathi N Pillai; Jeffry Evans; Ian Chau; Petri Bono; Akin Atmaca; Padmanee Sharma; Christopher T Harbison; Chen-Sheng Lin; Olaf Christensen; Emiliano Calvo
Journal:  Lancet Oncol       Date:  2016-06-04       Impact factor: 41.316

7.  Patients with lung cancer and paraneoplastic Hu syndrome harbor HuD-specific type 2 CD8+ T cells.

Authors:  Wendy K Roberts; Ilana J Deluca; Ashby Thomas; John Fak; Travis Williams; Noreen Buckley; Athanasios G Dousmanis; Jerome B Posner; Robert B Darnell
Journal:  J Clin Invest       Date:  2009-06-08       Impact factor: 14.808

8.  Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer.

Authors:  Martin Peifer; Lynnette Fernández-Cuesta; Martin L Sos; Julie George; Danila Seidel; Lawryn H Kasper; Dennis Plenker; Frauke Leenders; Ruping Sun; Thomas Zander; Roopika Menon; Mirjam Koker; Ilona Dahmen; Christian Müller; Vincenzo Di Cerbo; Hans-Ulrich Schildhaus; Janine Altmüller; Ingelore Baessmann; Christian Becker; Bram de Wilde; Jo Vandesompele; Diana Böhm; Sascha Ansén; Franziska Gabler; Ines Wilkening; Stefanie Heynck; Johannes M Heuckmann; Xin Lu; Scott L Carter; Kristian Cibulskis; Shantanu Banerji; Gad Getz; Kwon-Sik Park; Daniel Rauh; Christian Grütter; Matthias Fischer; Laura Pasqualucci; Gavin Wright; Zoe Wainer; Prudence Russell; Iver Petersen; Yuan Chen; Erich Stoelben; Corinna Ludwig; Philipp Schnabel; Hans Hoffmann; Thomas Muley; Michael Brockmann; Walburga Engel-Riedel; Lucia A Muscarella; Vito M Fazio; Harry Groen; Wim Timens; Hannie Sietsma; Erik Thunnissen; Egbert Smit; Daniëlle A M Heideman; Peter J F Snijders; Federico Cappuzzo; Claudia Ligorio; Stefania Damiani; John Field; Steinar Solberg; Odd Terje Brustugun; Marius Lund-Iversen; Jörg Sänger; Joachim H Clement; Alex Soltermann; Holger Moch; Walter Weder; Benjamin Solomon; Jean-Charles Soria; Pierre Validire; Benjamin Besse; Elisabeth Brambilla; Christian Brambilla; Sylvie Lantuejoul; Philippe Lorimier; Peter M Schneider; Michael Hallek; William Pao; Matthew Meyerson; Julien Sage; Jay Shendure; Robert Schneider; Reinhard Büttner; Jürgen Wolf; Peter Nürnberg; Sven Perner; Lukas C Heukamp; Paul K Brindle; Stefan Haas; Roman K Thomas
Journal:  Nat Genet       Date:  2012-09-02       Impact factor: 38.330

9.  Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial.

Authors:  M Reck; I Bondarenko; A Luft; P Serwatowski; F Barlesi; R Chacko; M Sebastian; H Lu; J-M Cuillerot; T J Lynch
Journal:  Ann Oncol       Date:  2012-08-02       Impact factor: 32.976

10.  ESMO-Magnitude of Clinical Benefit Scale version 1.1.

Authors:  N I Cherny; U Dafni; J Bogaerts; N J Latino; G Pentheroudakis; J-Y Douillard; J Tabernero; C Zielinski; M J Piccart; E G E de Vries
Journal:  Ann Oncol       Date:  2017-10-01       Impact factor: 32.976

View more
  2 in total

Review 1.  What is the role of radiotherapy for extensive-stage small cell lung cancer in the immunotherapy era?

Authors:  Eric G Nesbit; Ticiana A Leal; Tim J Kruser
Journal:  Transl Lung Cancer Res       Date:  2019-09

Review 2.  [Progress on PD-1/PD-L1 Checkpoint Inhibitors in Lung Cancer].

Authors:  Di Zhang; Jiaqi Huang; Chufeng Zhang; Yan Guan; Qisen Guo
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2019-06-20
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.